Autonomix Medical Secures New U.S. Patent for Precision Neuromodulation Platform
THE WOODLANDS, Texas, July 23, 2026 Autonomix Medical, Inc. announced that it has been granted U.S. Patent No. 12,471,776,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
THE WOODLANDS, Texas, July 23, 2026 Autonomix Medical, Inc. announced that it has been granted U.S. Patent No. 12,471,776,...
THE WOODLANDS, Texas, July 13, 2026 Autonomix Medical announced the grant of Canadian Patent No. 3,158,197, titled “Endoscopic Sympathectomy...
February 25, 2026 – The Woodlands, Texas, USA Autonomix Medical, Inc. has announced the release of a new CEO...
